Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyrotinib + paclitaxel
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Pyrotinib + paclitaxel is a combination therapy consisting of an irreversible pan-ErbB tyrosine kinase inhibitor and a microtubule-stabilizing taxane. Pyrotinib targets the intracellular kinase domains of EGFR, HER2, and HER4, inhibiting downstream signaling pathways like PI3K/Akt and MAPK. Paclitaxel interferes with microtubule dynamics during mitosis, leading to cell cycle arrest and apoptosis. This combination is primarily investigated for HER2-positive malignancies, including advanced or metastatic gastric and gastroesophageal junction cancers, where it aims to overcome resistance and provide synergistic anti-tumor activity. Clinical trials, such as those sponsored by He'nan Provincial People's Hospital, evaluate this regimen in patients who have failed prior therapies.
- Brand names
- Airuini
- Other names
- pyrotinib + paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on pyrotinib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyrotinib + paclitaxel.